Close menu




November 8th, 2019 | 07:50 CET

BMW, NEL ASA, IWATER GROUP - TODAY RECOGNIZE THE TOPICS OF THE FUTURE

  • Innovations
Photo credits: pixabay.com

This week, the German government decided to create incentives to buy e-mobility with higher subsidies. For example, government support for the purchase of a new car was increased from EUR 4,000 to EUR 6,000. The large car batteries of the electric cars, however, can lead to an extended problem of electronic scrap at landfills all over the world due to a lack of recycling methods and infrastructure if solutions are not worked out at the same time.

time to read: 2 minutes | Author: Mario Hose
ISIN:

Table of contents:


    WHO WILL BUY BATTERY CARS?

    The carmakers BMW, Daimler and Volkswagen have politicians on their side for more support to drive the electromobility project forward. The current sales figures for battery cars are sober. Despite all the marketing measures, according to the Federal Motor Transport Authority, 47,903 battery-powered cars were registered in Germany in the first nine months of 2019, which corresponds to just 1.7% of the total number of 2,740,158 passenger cars. Battery cars are expected to play a role in the future mobility mix, but no technology is free.

    WHO TAKES CARE OF ELECTRONIC SCRAP?

    The lithium-ion batteries used to power electric cars of all kinds are made of metals that are degraded under considerable environmental and human stress and do not last forever. For example, with a low battery weight of 250 kilograms, 1,000,000 cars generate an additional 250,000 tons of waste. Powerful vehicles like the Tesla S have batteries weighing over 700 kilograms on board.

    WHO BEARS THE COSTS OF RECYCLING?

    The batteries of the various battery manufacturers have different standards, which does not make recycling any easier. It is also important to bear the costs, because recycling will become costly. Before we get there, there is another important question: Where should all the raw materials for the batteries come from? The annual demand for lithium is expected to exceed the current production rates from the mines as early as 2022 and by 2050 the demand for cobalt could exceed the known planetary reserves.

    WHEN WILL THE HYDROGEN FILLING STATION NETWORK BE IN PLACE?

    A real alternative to a purely battery-powered vehicle is the fuel cell. The refuelling process in connection with hydrogen technology is comparable with petrol and diesel on the basis of duration and range. In Germany there is a nationwide network of around 14,000 filling stations offering petrol and diesel.

    A similar number of hydrogen filling stations will probably be sufficient to make hydrogen technology socially acceptable. A much smaller number compared to millions of charging stations for battery cars. The Norwegian company NEL ASA develops devices for the production of hydrogen and thus plays an interesting role in connection with the development of a filling station network for this energy carrier.

    WHO CLEANS WATER IN AN ENVIRONMENTALLY FRIENDLY WAY?

    The waste product of the fuel cell is water, and iWater Group Limited is also concerned with this future topic. With its products and processes, the company focuses on the purification of contaminated water. According to the company, products have been used worldwide in agriculture, food processing, livestock farming and oil & gas since 2018. Since then, they have ensured environmentally compatible purification of water and a reduction in the use of antibiotics and pesticides.

    Last month, the former CEO of Kühne + Nagel, Reinhard Lange, was appointed to the company's Executive Board with responsibility for Globalization & Logistics. Water, the staple food, will gain in importance and the topic of cleaning will continue to occupy us more in the future.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Nico Popp on June 18th, 2026 | 07:35 CEST

    The Secret Mechanism That Kills Cancer Cells: What Revolution Medicines and Merck & Co. Need to Learn from Vidac Pharma

    • Biotechnology
    • Biotech
    • Pharma
    • Cancer
    • Innovations

    There is, without exaggeration, a looming "patent cliff" of enormous scale: an estimated USD 236 billion in annual revenue losses are forcing the biopharmaceutical industry to find new paths forward. Pharma giants must replace dwindling blockbuster revenues by strategically acquiring innovative oncology platforms, as conventional cancer therapies are increasingly reaching their limits. This innovation pressure is triggering a consolidation wave in which research-driven biotech companies with protected mechanisms of action are moving into the center of potential takeover activity. In particular, intracellular and metabolic treatment approaches are rapidly gaining importance in the fight against treatment-resistant cancers. We take a look at Revolution Medicines' successes and identify the next potential high-flyer.

    Read

    Commented by Stefan Feulner on June 15th, 2026 | 07:40 CEST

    Nurix, BioNxt Solutions, Zealand Pharma: New Therapies Ignite the Imagination

    • Biotechnology
    • Biotech
    • Pharma
    • Cancer
    • Innovations

    The biotech sector is currently experiencing tremendous momentum. Therapies for obesity, diabetes, autoimmune diseases, and neurological conditions, in particular, rank among the largest growth markets in the healthcare industry. The booming GLP-1 market for weight loss and metabolic disorders alone is expected to reach a volume of tens of billions of USD in the coming years. At the same time, new classes of active ingredients and innovative delivery technologies are providing fresh momentum. Investors find themselves in an environment where clinical advances and technological innovations can trigger significant increases in value.

    Read

    Commented by Carsten Mainitz on April 10th, 2026 | 08:20 CEST

    Unlocking Massive Potential in Pharma's Largest Segment: Innovator Vidac Pharma, Industry Leader Bayer, or Turnaround Candidate Evotec?

    • Biotechnology
    • Healthcare
    • Innovations
    • Cancer
    • Pharma

    Oncology is the most strategically important growth market in the pharmaceutical industry and at the same time one of the key levers for improving global health. Currently, around 20 million people worldwide are diagnosed with cancer each year, a figure expected to exceed 30 million annually by 2040. The global oncology drug market is already valued at over USD 200 billion and continues to expand rapidly. Bayer aims to rank among the world's leading oncology players by 2030 and recently reaffirmed its medium-term targets. Following the sale of a stake in a cancer specialist, shareholders of Evotec, which has faced significant pressure, may soon benefit from a welcome inflow of funds. Vidac Pharma, on the other hand, is breaking new ground in the fight against skin cancer. There is enormous potential here.

    Read